Peripheral Blood Mononuclear Cells

Peripheral blood mononuclear cells are collected from healthy donors by leukapheresis and further purified on ficoll-sodium metrizoate density gradients. The cells are washed extensively and frozen in a solution of 10% DMSO, 2% human serum albumin in phosphate buffered saline. Donors are tested for the blood borne pathogens HIV-1/ 2 Antibody, Hepatitis B Surface Antigen and Core Antibody, HCV Antibody, HTLV-I/II, syphilis, NAT HIV/HCV, NAT WNV and found to be negative. Cells should still be handled as if potentially infectious following biosafety level 2 procedures.

Our PBMCs are available in 3 sizes:

 

Cells/Vial Price
5-10M $85.00
20-49M $165.00
50-99M $225.00

 

* Hover over Donor to view donor details

Catalog Number Product Name Donor Size Price In Stock
1001-2170MY13 PBMC 50M

50-99 M cells/vial $225.00 2
1001-2607MY14 PBMC 50M

 

Donor:153 M1 Peptide:N/T
Blood Type:O pos CMV Antigens:pos
Age:26 Tetanus Toxoid:pos
Gender:F LPS:pos
Ethnicity:Caucasian PHA:pos
HLA-A *31 *02
HLA-B *57 *15
HLA-C *06 *03
HLA-DRβ1 *13 *15
Donor is Fc gamma RIIIa-158 F/F
50-99 M cells/vial $225.00 54
1001-2584AP14 PBMC 50M

 

Donor:155 M1 Peptide:N/T
Blood Type:O pos CMV Antigens:neg
Age:49 Tetanus Toxoid:pos
Gender:M LPS:pos
Ethnicity:Caucasian PHA:pos
HLA-A *24 *02
HLA-B *15 *07
HLA-C *07 *03
HLA-DRβ1 *15 *11
50-99 M cells/vial $225.00 12
1001-2618JN14 PBMC 50M

 

Donor:165 M1 Peptide:N/T
Blood Type:O pos CMV Antigens:pos
Age:50 Tetanus Toxoid:neg
Gender:M LPS:pos
Ethnicity:Caucasian PHA:pos
HLA-A *24 *11
HLA-B *35 *07
HLA-C *07 *04
HLA-DR *15 *11
Donor is Fc gamma RIIIa-158 V/F
50-99 M cells/vial $225.00 48
1000-2600AP14 PBMC 20M

 

Donor:315 M1 Peptide:N/T
Blood Type:O pos CMV Antigens:N/T
Age:50 Tetanus Toxoid:N/T
Gender:M LPS:N/T
Ethnicity:Caucasian PHA:N/T
HLA-A *31 *02
HLA-B *51 *44
HLA-C *05 *05
HLA-DRB1 *13 *12
HLA-DQB1 *03 *03
Fc gamma RIIIa 158 F/V
20-49 M cells/vial $165.00 7
1000-2632JN14 PBMC 20M

 

Donor:330 M1 Peptide:N/T
Blood Type:A pos CMV Antigens:neg
Age:46 Tetanus Toxoid:pos
Gender:M LPS:pos
Ethnicity:Caucasian PHA:pos
HLA-A *02 *01
HLA-B *57 *52
HLA-C *12 *06
HLA-DRB1 *08:03 *04:01
HLA-DQB1 *03 *03
Fc gamma RIIIa 158 F/V
20-49 M cells/vial $165.00 34
1001-2628JN14 PBMC 50M

 

Donor:330 M1 Peptide:N/T
Blood Type:A pos CMV Antigens:neg
Age:46 Tetanus Toxoid:pos
Gender:M LPS:pos
Ethnicity:Caucasian PHA:pos
HLA-A *02 *01
HLA-B *57 *52
HLA-C *12 *06
HLA-DRB1 *08:03 *04:01
HLA-DQB1 *03 *03
Fc gamma RIIIa 158 F/V
50-99 M cells/vial $225.00 10
1000-2648JY14 PBMC 20M

 

Donor:337 M1 Peptide:N/T
Blood Type:O pos CMV Antigens:pos
Age:45 Tetanus Toxoid:pos
Gender:M LPS:pos
Ethnicity:Hispanic PHA:pos

Genetic typing can be performed for an additional charge.

20-49 M cells/vial $165.00 11

Storage

Store in the vapor phase of liquid nitrogen (< minus 120°C). Product may be stored at < minus 75°C for several days but cell viability will decrease with extended storage.

Testing

Cell count, cell viability and antigen responses are reported on each lot.

FACS

 

Publications

Publications using PBMC from Astarte Biologics

J Tan, X Wang, K Devadas, J Zhao, P Zhang, I Hewlett Some mechanisms of FLIP expression in inhibition of HIV‐1 replication in Jurkat cells, CD4+ T cells and PBMCs
 - Journal of cellular physiology, 2013

VA VanderNoot, SA Langevin, OD Solberg, PD Lane Materials and methods E. coli K-12 and human PBMC cDNA library preparation BioTechniques, 2012

LA Solt, TM Kamenecka, TP Burris LXR-Mediated Inhibition of CD4+ T Helper Cells PLOS ONE, 2012

SR Kuo, L Wong Engineering a CD123xCD3 bispecific scFv immunofusion for the treatment of leukemia and elimination of leukemia stem cells Protein Engineering Design and Selection, 2012

N Vaish, P Agarwal -The Design, Selection, and Evaluation of Highly Specific and Functional siRNA Incorporating Unlocked Nucleobase Analogs Methods in molecular biology (Clifton, NJ), 2013

White RA, et al.  Digital PCR provides absolute quantitation of viral load for an occult RNA virus. J Virol Methods, 2011 doi:10.1016/j.jviromet.2011.09.017

LA Solt, N Kumar, P Nuhant, Y Wang, JL Lauer, et al. 2011 Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand Nature, 472:491  abstract

El-Hage N, et al.  HIV-1 co-infection and Morphine Co-Exposure Severely Dysregulate HCV-induced hepatic pro-inflamatory cytokine release and free radical production:  increased pathogenesis coincides with uncoordinated host-defenses.  J Virology 2011. published online ahead of print, Sept 7, 2011 abstract

Vuletic S, et al. PLTP Regulates STAT3 and NF [kappa] B in Differentiated THP-1 cells and human monocyte-derived macrophages. Biochim Biophys Acta 2011, abstract

Debebe Z, et al. Iron Chelators of the DpT and BpT Series Inhibit HIV-1 Transcription: Identification of novel cellular targets - Iron, cdk2 and cdk9. Mol. Pharmacology 2010, full text

Xiong G, et al. Novel cancer vaccine based on genes of Salmonella pathogenicity island 2. Int J Cancer 2010,126:2622-2634. abstract

Song L,  et al.  Vα24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages.  J Clin Invest 2009, 119:1524-1536     www.pubmedcentral.nih.gov/articlerender.fcgi

Klinghoffer RA, Frazier J, Annis J, Berndt JD, Roberts BS, et al. 2009 A Lentivirus-Mediated Genetic Screen Identifies Dihydrofolate Reductase (DHFR) as a Modulator of β-Catenin/GSK3 Signaling. PLoS ONE 4(9): e6892. doi:10.1371/journal.pone.0006892   http://www.plosone.org/article

Song L, et al.  Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma J Clin Invest 2007, 117:2702-2712. full text

 FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.